Navigation Links
Zysolin(TM) Pre-clinical Data Supports Once-a-day Dosing in Humans
Date:6/18/2009

    AlphaRx's inhaled Tobramycin nanoparticle formulation provides 300% more
    availability than standard free drug in lung tissue, as demonstrated in a
    recent animal pharmacokinetic study.

MARKHAM, ON, June 18 /PRNewswire-FirstCall/ - AlphaRx (OTC BB:ALRX) is pleased to report a significant breakthrough in the development of Zysolin(TM), an inhaled Tobramycin nanoparticle formulation utilizing the company's proprietary drug delivery platform, and intended for the adjunctive treatment of Pseudomonas Aeruginosa Pneumonia in intubated and mechanically-ventilated patients (VAP).

In a recent pivotal animal PK (pharmacokinetic) study, Zysolin(TM) delivered 300% more drug to lung tissue than free drug, when utilizing the same delivery method. This data demonstrates that Zysolin(TM) provides superior lung tissue penetration and a release profile which supports once-a-day human dosing frequency.

The study data will be presented, by invitation, to the upcoming July meeting of the Controlled Release Society Conference in Copenhagen, Denmark.

Dr. Michael Weisspapir, MD, PhD, Chief Medical Scientist of AlphaRx commented, "As a result of this pre-clinical data, we anticipate that the demonstrated superiority over free drug availability will result in higher drug concentrations in lung tissue, enhancing clinical efficacy for VAP patients in vivo."

About Zysolin(TM)

Zysolin(TM) is a Tobramycin compound, encapsulated in AlphaRx's Nano Drug Delivery Platform, intended for the adjunctive treatment of Gram-negative pneumonia in intubated and mechanically-ventilated patients. Zysolin(TM) improves the intracellular activity of Tobramycin - in layman's term, increasing the drug concentration of Tobramycin inside human macrophages, thus improving its antibacterial activity against intracellular Klebsiella, Pseudomondas aeruginosa and Staphylococcus bacterial strains in pneumonia patients. The active ingredient in Zysolin(TM), Tobramycin, has a long-standing and proven clinical treatment record. Delivered by inhalation, using proprietary nanotechnology developed by AlphaRx, the company believes Zysolin(TM) will have an attractive safety, tolerability and efficacy profile when compared to injectible Tobramycin.

About AlphaRx Inc.

AlphaRx is a specialty pharmaceutical company dedicated to developing proven therapies by reformulating FDA approved and marketed drugs which through the application of its proprietary site-specific nano drug delivery technology, offers improved medical benefits and a potential for significant commercial product development.

Forward Looking Statements:

This release contains forward-looking statements within the meaning and pursuant to the Safe Harbor provisions of the Securities Litigation Reform Act of 1995 and involve risks and uncertainties that may individually or mutually impact the matters herein described, including but not limited to product development and acceptance, manufacturing, competition, regulatory and/or other factors, which are outside the control of the companies.


'/>"/>
SOURCE AlphaRx Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. PointCross Releases Pre-Clinical Study Lifecycle and Data Management Suite (PC-LDM(TM)) For Multi-Party Environments
2. Data Show SuperGens Multi-Targeted Tyrosine Kinase Inhibitor Demonstrates Pre-clinical Activity in Glioblastoma Multiforme
3. Akela Pharma receives letter from the FDA regarding its pre-clinical toxicology studies for Fentanyl TAIFUN(R)
4. Bioniche Presents Pre-Clinical Research at Two International Conferences
5. Senesco Announces Results of Pre-Clinical Efficacy, Toxicology and Dose Ranging Studies for Multiple Myeloma Therapeutic Candidate
6. Drug inhibits neuroblastoma blood supply in pre-clinical tests
7. Drug therapy reduces neuroblastoma tumor growth in pre-clinical investigation
8. HealthFitness CEO Supports Move Toward Cultural Shift, and Science-Based Health Management Programming
9. Diageo Supports First Ever National We Dont Serve Teens Week
10. The Prem Rawat Foundation Supports Disaster-Relief Efforts in Mozambique
11. Discovery supports theory of Alzheimers disease as form of diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... ... March 23, 2017 , ... Catalent Pharma Solutions, ... biologics and consumer health products, today announced that it had won the ‘Clinical ... at the Suntec Singapore International Exhibition & Convention Centre, Singapore. The award was ...
(Date:3/22/2017)... ... 2017 , ... Old School Labs™, makers of the best-selling Vintage line of ... Ambassador. Theophane, who trained with Floyd Mayweather, made his professional debut in London in ... an impressive number of wins in contests in Britain, Germany and the U.S. ...
(Date:3/22/2017)... ... 22, 2017 , ... Wash Tower Ltd. has released a series of six ... the world's first standalone constant pressure bidet. , The videos in the series titled ... https://www.washtower.com as well as on its social media pages. , Each video stars ...
(Date:3/22/2017)... (PRWEB) , ... March 22, 2017 , ... Drs. Jennifer ... their patient base to accept new patients in need of skilled pediatric dentistry ... India Hook Dental Care offers pediatric patients routine treatments, including cavities, sealants and fluoride ...
(Date:3/22/2017)... ... March 22, 2017 , ... ... lab with extensive therapeutic experience and operational excellence in oncology clinical trials, proudly ... trial for the treatment of non-small cell lung cancer and small cell lung ...
Breaking Medicine News(10 mins):
(Date:3/22/2017)... 22, 2017 FinancialBuzz.com News Commentary ... rapidly due to the significant development and innovation in ... Market Research, the global electrophysiology market was worth $3.42 ... billion by 2022, with a GAGR of 13.4%. Electrophysiology ... diagnose abnormal heartbeats or arrhythmia. The report indicates that ...
(Date:3/22/2017)... GROVE, Minn. , March 22, 2017   Upsher-Smith ... Clomipramine Hydrochloride Capsules* USP, 25 mg, 50 mg and 75 ... (clomipramine hydrochloride) Capsules USP. The clomipramine hydrochloride ... the 12 months ending December 2016, according to IMS Health. ... "Upsher-Smith ...
(Date:3/22/2017)... 22, 2017  As the world,s leading non-profit dedicated ... (LLS) has played a role in most therapies used ... are even helping patients with other cancers and serious ... investment in cutting-edge research – more than $1 billion ... with the record-breaking sum of $4.1 million raised at ...
Breaking Medicine Technology: